Objective. Interstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but very little is known about its long-term progression. This study was undertaken to investigate the progression of pulmonary disease using a large singlecenter cohort of patients with RA-associated ILD.
Methods. Records of all patients with RA-associated ILD seen at Mayo Clinic between 1998 and 2014, with at least 4 weeks follow-up and at least 1 pulmonary function test, were identified and manually screened for study inclusion. Progression was defined as a diffusing capacity for carbon monoxide (DLCO) <40% predicted (or patients whose illness was too advanced to undergo screening) or a forced vital capacity (FVC) <50% predicted. Time to progression was analyzed using the Kaplan-Meier method.
Results. Of the 167 patients included in the study, 81 (49%) were female, with a mean 6 SD age of 67 6 10 years at diagnosis of ILD. Median follow-up time from diagnosis of ILD was 3.3 years (range 0.01-14.8). Onethird of the patients required supplemental oxygen, 40% developed DLCO <40% predicted, and 22% developed FVC <50% predicted within 5 years after ILD diagnosis. Usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) was a risk factor for DLCO progression (hazard ratio 3.29 [95% confidence interval 1.28-8.41]). Lower DLCO and FVC at baseline increased the risk for progression to DLCO <40% predicted and FVC <50% predicted, and higher rates of change in the first 6 months also increased the risk of progression.
Conclusion. Progressive loss of pulmonary function is common in RA-associated ILD and is worse in patients with UIP than in those with NSIP. Predictors of progression in patients with RA-associated ILD may aid clinicians in identifying patients at highest risk for progression of ILD.
Lung disease is a relatively common extraarticular manifestation of rheumatoid arthritis (RA), which can present with a restrictive and/or obstructive pattern, and is often clinically underrecognized (1,2). Significant restrictive lung disease, most commonly interstitial lung disease (ILD), occurs in 8-15% of patients with RA (3, 4) . Clinical symptoms are variable (most commonly dyspnea and cough), with the illness causing rapid deterioration in some patients while others remain relatively stable (5) . The 3 main types of RA-associated ILD are usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), and organizing pneumonia (OP), of which UIP is the most common (6, 7) .
Currently, there are only limited data on rates of change in lung disease in patients with RA-associated ILD, and uncertainty persists regarding which outcome measures are best to assess progression (8) . Clinical evaluation and histopathologic sampling along with highresolution computed tomography (HRCT) are sensitive for detection and classification of ILD, while pulmonary function testing (PFT) may be better suited for assessing progression (6, 9) . Pulmonary physiology has recently been shown to predict mortality independent of HRCT pattern (10) . Therefore, it is likely that evaluation of the rates of change by PFT in this patient population will provide a needed tool in assessing progression.
In patients with idiopathic pulmonary fibrosis (IPF), forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) are the most sensitive parameters for assessing the clinical course (11) . Evaluation of pulmonary hypertension (PH) in patients with IPF is also important, as it is relatively common in these patients and has been associated with more rapid progression to low DLco and increased risk of death from pulmonary complications (12) .
There is a strong correlation between progressively lower values of FVC and DLco and significant morbidity and clinical disease severity in ILD, especially IPF (11) . Consensus opinion from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation states that pulmonary testing parameters for candidate selection for lung transplantation in patients with ILD should focus on FVC, DLco, and PH by right-sided heart catheterization or echocardiography, as these measures are associated with poor quality of life and poor prognosis (13) . These parameters are also likely those of most interest in assessing pulmonary decline in patients with RA-associated ILD. In the present study we utilized a large, single-center cohort of patients with RA-associated ILD to describe the progression of pulmonary disease, using measures of pulmonary physiology.
PATIENTS AND METHODS
Study population. This retrospective cohort study was approved by the Mayo Clinic Institutional Review Board. Study subjects were identified through a unified, single-center, electronic medical record system using International Classification of Diseases, Ninth Revision codes for ILD with diagnosis occurring between January 1, 1998 and December 31, 2014. All identified cases that fulfilled the 1987 American College of Rheumatology criteria for RA (14) , with a minimum of 4 weeks of follow-up, chest HRCT, and at least 1 PFT, were subsequently manually reviewed for verification of ILD diagnosis (15) . Patients with concomitant rheumatic disease other than RA-related secondary Sj€ ogren's syndrome (such as systemic lupus erythematosus, vasculitis, etc.) were excluded. Individuals with ILD and concomitant obstructive lung disease (defined as obstructive airway diseases, emphysema, chronic bronchitis, or asthma) were included. Only tests performed at the study center were abstracted for analysis.
Data collection. PFT results were recorded in both volume (liters) and percent predicted values, and data recorded between 1 year prior to diagnosis of ILD and 10 years after diagnosis were abstracted. All PFTs in the 12 months before or after ILD diagnosis and the first PFT for each subsequent follow-up year were included. Parameters included FVC, forced expiratory volume in 1 second (FEV 1 ), total lung capacity (TLC), and DLco. The DLco results were corrected for hemoglobin level when appropriate for each individual PFT. If baseline DLco values were unavailable, reasons for this were also manually abstracted. Transthoracic echocardiograms (TTEs) were manually reviewed for the presence of PH, defined as estimated right systolic ventricular pressure .35 mm Hg (12) . TTE data recorded included date of first study, date when definition of PH was met (if available), and total number of TTEs per patient. Data collected on resting oxygen supplementation included need at ILD diagnosis, date of first oxygen prescription (if available), and oxygen requirement (in liters) at last follow-up.
Data on RA therapies and disease severity indicators were also collected by manual record review. Data abstracted on RA therapies at and after ILD diagnosis included prednisone (categorized as #10 mg per day or .10 mg per day), as well as biologic and nonbiologic immunosuppressive agents. Data abstracted on disease severity included rheumatoid factor, anti-citrullinated protein antibodies, presence of rheumatoid nodules, erosions, and any additional extraarticular manifestations other than ILD. Severe extraarticular manifestations were defined according to the Malm€ o criteria (16) and included pericarditis, pleuritis, Felty's syndrome, glomerulonephritis, vasculitis, peripheral neuropathy, scleritis, and episcleritis. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values closest to and within 30 days of diagnosis of ILD were also recorded when available. We abstracted follow-up data through 10-year follow-up, December 31, 2015, or death.
Statistical analysis. Descriptive statistics were used to summarize the data. Comparisons between groups were performed using chi-square and rank sum tests. Progression was defined as the first occurrence of a DLCO ,40% predicted (or those patients who were too ill to undergo the DLCO testing) and/or an FVC ,50% predicted (severe restriction). Time to progression was analyzed using the Kaplan-Meier method and Cox models adjusted for age and sex. PH was modeled using time-dependent covariates. For data analysis purposes, patients were not considered to be at risk for PH until the time the first TTE was performed. Medications for RA were divided into distinct groups and were analyzed using time-dependent covariates that began when the medication was first used and stopped 30 days after the medication was discontinued (to allow for a washout period).
The 6-month rate of change in DLco and FVC was estimated using the PFT measures obtained closest to diagnosis of ILD (6 6 months) and closest to 6 months after ILD diagnosis (up to 1 year). To ensure comparability across patients, 6-month rate of change was calculated as the absolute change in percent predicted DLco or FVC between the 2 measures, divided by the number of days between the measures, and multiplied by the number of days in 6 months. Nonlinear effects were examined using smoothing splines. Analyses were performed using SAS version 9.4 (SAS Institute) and R 3.1.1 (R Foundation for Statistical Computing).
RESULTS
A total of 167 patients were included in our cohort. The majority of the patients (97%) were Caucasian and 81 (49%) were female; their mean 6 SD age at the time of ILD diagnosis was 67 6 10 years (Table 1) . Sixty-two of the patients (37%) were never smokers. During follow-up, 68 patients died (including 20 whose deaths were directly attributable to pulmonary disease). A total of 89 (53%) had UIP, 70 (42%) had NSIP, and 8 (5%) had RA-related OP. In 120 patients with available data, the median ESR at the visit closest to the time of ILD diagnosis was 34 mm/hour (normal 0-22 mm/hour in men and 0-29 mm/hour in women), with an interquartile range (IQR) of 19 to 53. In contrast, the median CRP (n 5 86 patients) was 17 mg/liter (normal 0-8 mg/liter), with an IQR of 5 to 34, with no significant differences between types of ILD. Erosive disease was documented in 41 patients (25%), and the most common additional extraarticular manifestations (apart from ILD) were subcutaneous nodules in 42 patients (25%).
At the time of diagnosis of ILD, supplemental oxygen was used in 23 patients (14%) and was required Table 1 for other definitions). † The mean 6 SD time from the first to the last pulmonary function test was 3.6 6 3.5 years, 3.6 6 3.1 years, and 3.3 6 3.1 years in the UIP, NSIP, and OP groups, respectively (P 5 0.84). A total of 564 PFTs were included in the analysis. Baseline PFTs at the time of ILD diagnosis (within 6 months) included a median percent predicted FVC of 71%, an FEV 1 of 70%, a TLC of 72%, and a DLCO of 54.5%. The median percent predicted DLCO was 51.5% for UIP, 57% for NSIP, and 71% for OP (P 5 0.006). Among types of ILD, there were no other significant differences in these PFT parameters at baseline (Table 2) . DLCO declined more within the first 6 months after diagnosis of ILD in patients with OP or UIP than in those with NSIP (median change in percent predicted was 213.7 in OP, 22.3 in UIP, and 2.2 in NSIP; P 5 0.04).
At diagnosis of ILD (including all PFTs up to 6 months after diagnosis), 48 patients (29%) had a DLCO of ,40% predicted, and 23 patients (14%) had an FVC of ,50% predicted. During follow-up, DLCO declined to ,40% predicted (or patients were too ill to undergo the test) in 22 additional patients, and 13 additional patients developed an FVC ,50% predicted, indicating severe restriction. Combining data at ILD diagnosis and during follow-up, by 5 years after ILD diagnosis, 39.7% (95% CI 31.0-47.3) of patients reached a DLCO ,40% predicted (or were too ill to undergo the test), and 21.6% (95% CI 14.4-28.2) of patients reached FVC ,50% predicted (Figure 1) . Among those who did not meet the definitions of progression at diagnosis of ILD, those with UIP were more likely to progress to a DLCO of ,40% predicted than those with NSIP (HR 3.29 [95% CI 1.28-8.41]) ( Figure  2 ). This association persisted after additional adjustment for baseline DLCO (HR 3.04 [95% CI 1.04-8.89]). Current or former smoking had a protective effect on progression to a DLCO of ,40% predicted (HR 0.35 [95% CI 0.14-0.85]). However, this association did not persist after adjustment for the percent predicted DLCO Figure 1 . Estimated percentage of patients with diffusing capacity for carbon monoxide ,40% predicted (or those who were too ill to undergo the test) (solid line) and with forced vital capacity ,50% predicted (broken line), according to time since interstitial lung disease (ILD) diagnosis in the 167 patients with rheumatoid arthritis and ILD. 
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(P 5 0.52). Other factors analyzed, including PH, did not reach statistical significance (Table 3) . There was no difference between UIP and NSIP in progression to an FVC of ,50% predicted (HR 0.86 [95% CI 0.27-2.73]) (Figure 2 For the FVC, the estimated rate of change in the first 6 months was a median increase of 1.0% predicted (IQR 25.0 to 7.0), and for the DLCO it was a median loss of 1.0% (IQR 26.0 to 5.0). There was a significant association between the 6-month rate of change in the DLCO and progression to a DLCO of ,40% predicted (HR 1.72 per 10-unit decrease [95% CI 1.07-2.74]) and between the 6-month rate of change in the FVC and progression to an FVC of ,50% predicted (HR 3.42 per 10-unit decrease [95% CI 1.61-7.24]). Analyses of potential nonlinear effects of a 6-month rate of change in the DLCO on the development of progression to a DLCO of ,40% predicted and of a 6-month rate of change in the FVC on * All models were adjusted for age and sex at ILD diagnosis. DLCO 5 diffusing capacity for carbon monoxide; HR 5 hazard ratio; 95% CI 5 95% confidence interval; FVC 5 forced vital capacity; ESR 5 erythrocyte sedimentation rate; CRP 5 C-reactive protein; SSZ 5 sulfasalazine; HCQ 5 hydroxychloroquine; MTX 5 methotrexate; LEF 5 leflunomide; DMARD 5 disease-modifying antirheumatic drug (see Table 1 for other definitions). † Per 10-unit increase. ‡ Per 10-unit decrease. § Developed pulmonary hypertension during follow-up. ¶ Having transthoracic echo (TTE) related to suspicion for pulmonary hypertension, not causation. # Per 10% decrease in first 6 months of follow-up. ** Alone or without any other antirheumatic drug or glucocorticoid. † † Alone or in combination with any other antirheumatic drug. Patients taking both a tumor necrosis factor inhibitor (TNFi) (or non-TNFi biologic agent, i.e., rituximab, abatacept) and prednisone .10 mg/day are in the TNFi (or non-TNFi) biologic group. 546 ZAMORA-LEGOFF ET AL the development of progression to an FVC of ,50% predicted did not reveal any significant nonlinear effects (P 5 0.31 and P 5 0.29, respectively). A total of 106 patients had $1 TTE performed as part of routine care, with a median of 2 TTEs per patient. Fourteen patients had a diagnosis of PH prior to diagnosis of ILD, and an additional 47 patients developed PH during follow-up. While the HRs were elevated for the association between PH and the progression to a DLCO of ,40% predicted and an FVC of ,50% predicted, these associations did not reach statistical significance (HR 2.65 [95% CI 0.93-7.58] and HR 1.26 [95% CI 0.32-5.04], respectively).
RA therapies during follow-up were categorized into distinct groups including sulfasalazine and/or hydroxychloroquine alone (n 5 34; 68. . No other significant associations were found due to the relatively low number of patients progressing within each medication group and the potential of confounding by indication (Table 3) .
DISCUSSION
In this study of the clinical course of pulmonary disease in a large, single-center cohort of patients with RA-associated ILD, we demonstrated that a progressive decline of pulmonary function is common and typically worse in patients with UIP than in those with NSIP. The illness is more likely to progress to severe impairment of pulmonary function in patients who experience a greater decline of this function in the first 6 months after diagnosis of ILD, as compared to patients whose pulmonary function remains relatively stable during this time. A lower pulmonary reserve at time of diagnosis of ILD (as measured by the DLCO and FVC) increased the risk of progression. Additionally, one-third of patients required supplemental oxygen within 5 years after diagnosis of ILD.
The findings of PFTs measured at baseline were similar among the subtypes of ILD, with the notable exception of the DLCO, which was lowest in patients with UIP when compared to those with NSIP or OP. Previous studies have shown that DLCO is the most sensitive PFT parameter for early detection of ILD and is an independent predictor of mortality (13, 17) . In this cohort, the percent predicted DLCO, both at baseline and within 6 months after diagnosis of ILD, was significantly associated with progression of UIP and NSIP.
At the time of diagnosis of ILD, there were no meaningful differences in FVC between patients with NSIP and those with UIP. During the first 6 months following diagnosis, the FVC increased modestly in more than half of the patients; the median change was an increase of 1.0% predicted. It is unknown whether this increase is a true and physiologically meaningful change or whether it is an artifact of testing. Additionally, there is uncertainty as to why current or former smoking was associated with a lack of progression to a DLCO of ,40% predicted but not with a lack of progression or a decline in FVC. In contrast, DLCO is usually lower in patients with ILD and concomitant emphysema, a condition which has been termed combined pulmonary fibrosis and emphysema (18) . While the HR for association between emphysema and DLCO progression was elevated in our cohort, it did not reach statistical significance (most likely due to the relatively small number of patients with RArelated ILD and emphysema).
Overall, the present findings suggest that changes in pulmonary function in FVC at baseline and within the first 6 months of diagnosis of ILD are sensitive predictors of progressive and significant loss of pulmonary function. In the current study, patients with UIP were more likely to progress to a DLCO of ,40% predicted than those with NSIP, complementing previous research findings showing that patients with UIP tend to have worse overall outcomes than those with NSIP (17) . Previous studies on patients with IPF showed that a UIP pattern and the extent of pulmonary fibrosis on HRCT of the chest are associated with more rapid disease progression (11) . Similarly, the current study suggests that a more rapid decline in pulmonary function in patients with RArelated ILD is also associated with a UIP pattern on HRCT. A prednisone dosage of .10 mg/day and use of DMARDs were both associated with progression of ILD, which likely reflect overall disease severity. Data were insufficient to draw conclusions about the impact of specific categories of traditional DMARDs, biologic agents, and drug combinations on pulmonary outcomes.
Elevation of pulmonary artery pressure as determined by echocardiography can be seen in as many as 28% of patients with RA, even in the absence of clinically evident cardiopulmonary disease (although measured pressures are generally only moderately elevated) (19) . This moderate elevation corresponds to mild PH. In contrast, others have found that a larger proportion of patients with IPF had PH and higher pressures on TTE (12) . The presence of PH in patients with ILD has been associated with a more rapid deterioration and worse disease outcomes than in those without PH (19) . In the current study, using information obtained at routine clinic visits rather than data obtained according to protocol, the presence of PH in RA-related ILD was significantly associated (although only marginally so) with a progressive loss of pulmonary function.
This study focused on patients encountered in clinical practice and those who were referred for multispecialty evaluation in a tertiary care center. This is both a strength and a limitation of the study. Data were gathered only for patients who presented with clinically evident ILD and RA; routine screening for subclinical disease is not typically performed for the majority of patients with RA. Moreover, this was not a prospective study. During patient follow-up, PFTs and TTEs were performed and interpreted by expert specialists according to standard procedures and techniques (which generally reduces intraoperative variability). The HRCT scans included in our study were performed at the time of initial diagnosis and closest to the date of the last follow-up for all patients and were evaluated by expert thoracic radiologists and subsequently reviewed and managed by expert subspecialty pulmonologists. The statistical power to examine risk factors for progression was limited by the small number of patients who met the threshold for progression during follow-up. Additionally, the absence of ethnic diversity may hinder the generalizability of the results to other populations, although little is known about RA-related ILD in other ethnic populations. This is the largest study of the progression of pulmonary disease as assessed by both FVC and DLCO pulmonary function measures in patients with RA-related ILD in long-term follow-up. We demonstrated that a progressive loss of pulmonary function was common and generally worse in patients with UIP than in those with NSIP. Within 5 years after diagnosis of ILD, the DLCO showed that 40% of patients experienced progression to severe pulmonary impairment, and the FVC showed that 22% had experienced progression, and one-third of the patients required supplemental oxygen at rest. A lower baseline for both the DLCO and FVC increased the risk of progression, and higher rates of change in the first 6 months after diagnosis of ILD increased the risk of severe pulmonary impairment over time. Predictors of progression in patients with RArelated ILD may aid clinicians in identifying the subset of patients who are at highest risk for progression of ILD and in making decisions about management. They may also serve as a tool for counseling both patients and their families.
